C
C Clemm
Researcher at Ludwig Maximilian University of Munich
Publications - 8
Citations - 768
C Clemm is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Chemotherapy & Ifosfamide. The author has an hindex of 6, co-authored 8 publications receiving 726 citations.
Papers
More filters
Journal ArticleDOI
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
Susanne Krege,Jörg Beyer,Rainer Souchon,Peter Albers,Walter Albrecht,Ferran Algaba,Michael Bamberg,István Bodrogi,Carsten Bokemeyer,Eva Cavallin-Ståhl,Johannes Classen,C Clemm,Gabriella Cohn-Cedermark,Stéphane Culine,Gedske Daugaard,Pieter H.M. De Mulder,Maria De Santis,Maike de Wit,Ronald de Wit,H. G. Derigs,Klaus Peter Dieckmann,Annette Dieing,Jean Pierre Droz,Martin Fenner,Karim Fizazi,Aude Flechon,Sophie D. Fosså,Xavier Garcia del Muro,Thomas Gauler,Lajos Géczi,Arthur Gerl,Jose Ramon Germa-Lluch,Silke Gillessen,Jörg T. Hartmann,Michael Hartmann,Axel Heidenreich,Wolfgang Hoeltl,Alan Horwich,Robert Huddart,Michael Jewett,Johnathan Joffe,William G. Jones,László Kisbenedek,Olbjørn Klepp,S. Kliesch,Kai Uwe Koehrmann,Christian K. Kollmannsberger,Markus A. Kuczyk,Pilar Laguna,Oscar Leiva Galvis,Volker Loy,Malcolm David Mason,Graham M. Mead,Rolf Mueller,Craig R. Nichols,Nicola Nicolai,Tim Oliver,D. Ondruš,Gosse O N Oosterhof,Luis Paz Ares,Giorgio Pizzocaro,Jörg Pont,Tobias Pottek,Thomas Powles,Oliver Rick,Giovanni Rosti,Roberto Salvioni,Jutta Scheiderbauer,Hans U. Schmelz,Heinz Schmidberger,Hans-Joachim Schmoll,Mark Schrader,Felix Sedlmayer,Niels E. Skakkebæk,Aslam Sohaib,Sergei Tjulandin,Padraig Warde,Stefan Weinknecht,Lothar Weissbach,Christian Wittekind,Eva Winter,Lori Wood,Hans von der Maase +82 more
TL;DR: F refinements in the treatment of early- and advanced-stage testicular cancer have emerged from clinical trials, and expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer.
Journal ArticleDOI
Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials.
Carsten Bokemeyer,Christian K. Kollmannsberger,Sally P. Stenning,Joerg T. Hartmann,Alan Horwich,C Clemm,Gerl A,C Meisner,Rückerl Cp,H.-J. Schmoll,Lothar Kanz,Tim Oliver +11 more
TL;DR: In this article, the role of single agent carboplatin chemotherapy in patients with metastatic seminoma based on the data from two randomised trials was studied and the outcome treated with either single agent CARP or cisplatin-based combination chemotherapy was compared.
Journal ArticleDOI
Prognosis after salvage treatment for unselected male patients with germ cell tumours.
TL;DR: Whereas patients with good-risk features may be adequately managed by conventional salvage treatment, the remaining patients carry a very poor prognosis and require innovative and more aggressive approaches.
Journal ArticleDOI
Treatment of patients with cisplatin‐refractory testicular germ‐cell cancer
Carsten Bokemeyer,Christian K. Kollmannsberger,Andreas Harstrick,Jörg Beyer,Arthur Gerl,Jochen Casper,Bernd Metzner,Jörg T. Hartmann,C Clemm,Hans-Joachim Schmoll,Lothar Kanz +10 more
TL;DR: In this article, the authors evaluated the use of paclitaxel in combination with cisplatin and/or ifosfamide in refractory testicular germ-cell tumors.
Journal ArticleDOI
Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience.
TL;DR: After 612 patient-years of observation no case of secondary leukaemia was observed among 119 surviving patients who had received etoposide as part of their treatment, indicating some evidence that cumulative experience translates into improved survival and cure rates for patients with poor-risk metastatic disease.